Clinical Trial Update: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update reports results from a Phase 2/3 study evaluating pegylated liposomal doxorubicin in combination with atezolizumab and/or bevacizumab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Doxil (liposomal doxorubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-04